Physician profile
Mark Webb
NPI 1992843742
$11,881.53
in general payments reported to CMS, 2019-2025
28 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,863 · 2020: $591 · 2021: $1,595 · 2022: $1,116 · 2023: $1,333 · 2024: $1,101 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $4,467.32 | 2019-2025 | Trintellix |
| Abbvie INC. | $1,638.12 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,025.09 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $719.65 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $555.37 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $420.24 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $400.07 | 2023-2025 | Sunosi, Auvelity |
| Tris Pharma INC | $332.77 | 2019-2025 | Dyanavel Xr |
| Allergan, INC. | $278.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $256.73 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $236.16 | 2022-2024 | Austedo, Austedo Xr |
| Eisai INC. | $198.42 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $198.02 | 2019-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $185.75 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $171.16 | 2025 | Cobenfy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $155.83 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.55 | 2021-2023 | Caplyta |
| Neurocrine Biosciences, INC. | $128.58 | 2019-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $120.35 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $49.36 | 2023-2024 | Quviviq |
| Corium, LLC | $38.35 | 2025 | Azstarys |
| Shire North American Group INC | $30.50 | 2019 | |
| Avanir Pharmaceuticals, INC. | $28.78 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.42 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.16 | 2025 | |
| Biogen, INC. | $17.62 | 2021 | |
| Adlon Therapeutics L.P. | $13.99 | 2020 | |
| Bausch Health US, LLC | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.